U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Huntington Beach Vape Shop - 562781 - 10/24/2018
  1. Compliance Actions and Activities

CLOSEOUT LETTER

Huntington Beach Vape Shop MARCS-CMS 562781 — Oct 24, 2018

Huntington Beach Vape Shop - 562781 - 10/24/2018

Delivery Method:
VIA UPS and Electronic Mail
Reference #:
1800927
Product:
Tobacco

Recipient:
Recipient Name
Jim Petty
Huntington Beach Vape Shop

365 Pilot Road
Suite B
Las Vegas, NV 89119
United States

jim.petty@icloud.com
iyad.sabbah77@gmail.com
Issuing Office:
Center for Tobacco Products

10903 New Hampshire Avenue
Silver Spring, MD 20993
United States


Dear Jim Petty:

On September 12, 2018, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Candy King Batch e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Candy King Batch e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children.

On September 19, 2018 and October 2, 2018, you sent FDA a response to the Warning Letter. In response to the Warning Letter, you stated you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.

Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov.

Sincerely,
/S/
Ele Ibarra-Pratt
Division Director
Office of Compliance and Enforcement
Center for Tobacco Products

VIA UPS and Electronic Mail

cc:

Azim Chowdhury
Keller and Heckman LLP
1001 G Street NW, Suite 500 West
Washington, DC 20001
chowdhury@khlaw.com

GoDaddy, LLC
abuse@godaddy.com

Shopify, Inc.
abuse@shopify.com